{"id":"NCT01995266","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual","officialTitle":"A Phase 3, Open-Label Study With Daclatasvir And Asunaprevir (DUAL) for Subjects With Genotype 1b Chronic Hepatitis C (HCV) Infection Who Are Intolerant or Ineligible to Interferon Alfa Therapies With or Without Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-28","primaryCompletion":"2015-07-31","completion":"2015-07-31","firstPosted":"2013-11-26","resultsPosted":"2019-07-11","lastUpdate":"2020-08-11"},"enrollment":218,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Asunaprevir","otherNames":["BMS-650032"]},{"type":"DRUG","name":"Daclatasvir","otherNames":["BMS-790052"]}],"arms":[{"label":"Asunaprevir + Daclatasvir","type":"EXPERIMENTAL"}],"summary":"Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV) Dual regimen (= Daclatasvir + Asunaprevir) and followed for an additional 24 weeks post-treatment in order to determine the safety and efficacy of the DCV DUAL regimen","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) at Post-Treatment Follow-up Week 24 (SVR24)","timeFrame":"24 Weeks after treatment discontinuation (Follow-up Week 24)","effectByArm":[{"arm":"All Subjects","deltaMin":91.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":38,"countries":["China","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":159},"commonTop":["Platelet Count Decreased","Upper Respiratory Tract Infection","Alanine Aminotransferase Increased","Neutrophil Count Decreased","Monocyte Count Decreased"]}}